var data={"title":"Ketamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ketamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6420?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ketamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ketamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ketamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ketamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45497290\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ketalar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185726\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ketalar;</li>\n      <li>Ketamine Hydrochloride Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185763\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        General Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185729\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">May administer atropine, scopolamine, or another drying agent prior to induction and at appropriate intervals to decrease hypersalivation. <b>Note:</b> Titrate dose for desired effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Induction of anesthesia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM: 6.5 to 13 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IV: 1 to 4.5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations (off-label dosing):  <b>Note:</b> lower doses may be used if adjuvant drugs (eg, midazolam) are administered (Miller 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM:  4 to 10 mg/kg (Green 1990; Miller 2010; White 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IV: 0.5 to 2 mg/kg (Miller 2010; White 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Maintenance of anesthesia: </i>May administer supplemental doses of one-half to the full induction dose or a continuous infusion of 0.1 to 0.5 mg/minute (per manufacturer). <b>Note:</b> To maintain an adequate concentration of ketamine for maintenance of anesthesia, 1 to 2 mg/minute has been recommended (White 1982); doses in the range of 15 to 90 mcg/kg/minute (~1 to 6 mg/minute in a 70-kg patient) have also been suggested (Miller 2010). Concurrent use of nitrous oxide reduces ketamine requirements. Recent laboratory/clinical studies support the use of low-dose ketamine to improve postoperative analgesia/outcome (Adam 2005; Menigaux 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Analgesia (subanesthetic dosing) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Acute pain:</i> Intranasal (off-label route): 0.5 to 1 mg/kg; may repeat in 10 to 15 minutes with 0.25 to 0.5 mg/kg if necessary (Andolfatto 2013; Corrigan 2015; Yeaman 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Chronic pain:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intranasal (off-label route): 10 mg every 90 seconds as needed until a maximum total dose of 50 mg is reached or pain relieved (Carr 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: <b>Note:</b> Various dosing protocols have been utilized. One suggested inpatient protocol is presented. Consider the concomitant use of a benzodiazepine (eg, lorazepam) to prevent or reduce psychotomimetic effects and glycopyrrolate for excessive salivation or lacrimation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial: IV infusion: 0.5 mg/kg over 6 hours. <i>If pain improved by 50% or more</i> after completion of initial dose, then continue infusion at 1.5 mg/kg/24 hours for 48 hours. <i>If pain not improved</i> after completion of initial dose, increase to 2 mg/kg over 12 hours. <i>If pain recurs</i> after initial improvement, titrate upwards by 50% to 100% every 24 hours as needed. Discontinue infusion if pulse &gt;110 bpm, SBP increases &gt;25% of baseline, sustained respiratory rate &lt;7, agitation or severe psychotomimetic effects (Okon 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral (off-label route): Initial: 0.5 mg/kg as a single dose to evaluate effect on pain and duration of effect; may increase dose in increments of 0.5 mg/kg as appropriate. For a continuous analgesic effect, may administer 3 to 4 times daily (Blonk 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Acute on chronic episodes of neuropathic pain, severe:</i> Continuous IV or SubQ (off-label route) infusion: 2.3 to 6.7 mcg/kg/minute (equivalent to 0.14 to 0.4 <b>mg</b>/kg/<b>hour</b>) (Hocking 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Postoperative opioid sparing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 2 to 4 mg/kg (Miller 2010; White 1982); may follow with a continuous infusion if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 0.2 to 0.8 mg/kg bolus (Miller 2010; Rem&eacute;rand 2009; White 1982; Zakine 2008); a maximum bolus dose of 50 mg was used in one study (Rem&eacute;rand 2009). May follow bolus dose with a continuous infusion if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous IV infusion: 2 mcg/kg/minute (equivalent to 0.12 <b>mg</b>/kg/<b>hour</b>) (Rem&eacute;rand 2009; Zakine 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Critically ill patients (as an adjunct to an opioid analgesic for non-neuropathic pain):</i> IV: Initial: 0.1 to 0.5 mg/kg bolus; followed by a continuous infusion of 0.83 to 6.7 mcg/kg/minute (equivalent to 0.05 to 0.4 <b>mg</b>/kg/<b>hour</b>) (SCCM [Barr 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Procedural sedation/analgesia (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: The IV route is preferred; however if IV route unavailable, may administer 4 to 5 mg/kg IM as a single dose; may give a repeat dose (range: 2 to 5 mg/kg) if sedation inadequate after 5 to 10 minutes or if additional doses are required. May consider prophylactic use of a benzodiazepine (eg, midazolam) before ketamine administration to reduce the risk of emergence reactions (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: 1 to 2 mg/kg (usual adult dose: 100 mg) over 1 to 2 minutes; may consider prophylactic use of a benzodiazepine (eg, midazolam) before ketamine administration to reduce the risk of emergence reactions (ACEP [Green 2011]; Chudnofsky 2000; Green 2000). If initial sedation inadequate or repeated doses are necessary to accomplish a longer procedure, may administer incremental doses of 0.5 to 1 mg/kg every 5 to 15 minutes as needed (ACEP [Green 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185746\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ketamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ketamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">May administer atropine, scopolamine, or another drying agent prior to induction and at appropriate intervals to decrease hypersalivation. <b>Note:</b> Titrate dose to effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pre-anesthetic sedation:</i> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;6 months: 3 mg/kg/dose (half dose per nostril) administered at least 15 minutes prior to mask induction (Diaz 1997; Lin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;2 years: 3 to 5 mg/kg/dose (half dose per nostril) administered at least 15 minutes prior to mask induction (Diaz 1997; Gautam 2007; Lin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to 7 years: 3 to 6 mg/kg/dose (half dose per nostril) administered 15 to 40 minutes prior to induction (Diaz 1997; Gautam 2007; Lin 1990; Roelofse 2004; Weksler 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children &le;8 years: 6 to 8 mg/kg/dose 20 to 30 minutes prior to surgery (Gutstein 1992; Turhanoglu 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Reported effective range: Infants 2 to 6 months: 8 mg/kg/dose; Infants &ge;7 months and Children: 8 to 10 mg/kg/dose; administer 15 to 45 minutes prior to surgery as a single agent (Lin 1990; Tanaka 2000; Van der Bijl 1991; Wang 2010; Zanette 2010). <b>Note:</b> When used in combination with midazolam, a lower rectal dose of 3 mg/kg/dose has been effective (Beebe 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction of anesthesia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents &lt;16 years: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 5 to 10 mg/kg has been reported and suggested by experts (Cot&eacute; 2013; Lin 2005; Sungur Ulke 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 to 3 mg/kg has been reported and suggested by experts (Cot&eacute; 2013; Lin 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 6.5 to 13 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 to 4.5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance of anesthesia:</i> Adolescents &ge;16 years: May administer supplemental doses of one-half to the full induction dose as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endotracheal intubation:</b> Limited data available: Infants, Children, and Adolescents: IV: 1 to 2 mg/kg as part of rapid sequence sedation (Ballow 2012; Furhman 2011; Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation/analgesia, procedural (off-label use):</b> Infants, Children, and Adolescents:<b> Note:</b> Due to risk of airway obstruction, laryngospasm, and apnea, ACEP only recommends use in patients &ge;3 months of age (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ketamine without propofol: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 4 to 5 mg/kg as a single dose; may give a repeat dose (range: 2 to 5 mg/kg) if sedation inadequate after 5 to 10 minutes or if additional doses are required (ACEP [Green 2011]). Some have recommended smaller doses (2 to 2.5 mg/kg) for minor procedures (eg, wound suture with local anesthetic) (McGlone 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 to 2 mg/kg over 30 to 60 seconds. If initial sedation inadequate or repeated doses are necessary to accomplish a longer procedure, may administer additional doses of 0.5 to 1 mg/kg every 5 to 15 minutes as needed (ACEP [Green 2011]; Asadi 2013; Berkenbosch 2004, Koruk 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: Infants &ge;3 months and Children: 3 to 6 mg/kg (half dose per nostril) (Gyanesh 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children and Adolescents: 3 to 5 mg/kg with oral midazolam 30 to 45 minutes before procedure (Barkan 2014; Norambuena 2013; Ozdemir 2004). <b>Note:</b> A higher dose (10 mg/kg) has been used successfully as monotherapy prior to procedures (Tobias 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Children 1 to 8 years: 1.5 to 3 mg/kg with midazolam as a single dose 20 minutes prior to painful procedure (Heinrich 2004; Ozdemir 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ketamine with propofol (&quot;ketofol&quot;):</i> Infants &ge;3 months, Children, and Adolescents: IV: 0.5 to 0.75 mg/kg of each agent. This combination has been used to decrease the dose of each agent required (ACEP [Godwin 2014]; Alletag 2012; Shah 2011; Willman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation/analgesia, critically ill patients:</b> Very limited data available: Infants &ge;5 months, Children, and Adolescents: Initial dose: IV: 0.5 to 2 mg/kg, then continuous IV infusion: 5 to 20 <b>mcg</b>/kg/minute; start at lower dosage listed and titrate to effect (Denmark 2006; Rock 1986; Tobias 1990; White 1982); doses as high as 60 <b>mcg</b>/kg/minute have been reported in patients with refractory bronchospasm (Youssef-Ahmed 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185730\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160060\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160061\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185708\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ketalar: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (20 mL); 50 mg/mL (10 mL); 100 mg/mL (5 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (1 mL); 100 mg/2 mL (2 mL); 100 mg/10 mL (10 mL); 20 mg/2 mL (2 mL); 50 mg/5 mL in NaCl 0.9% (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185693\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185765\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-III</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185710\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal (using parenteral dosage form): Use the 50 or 100 mg/mL solution; may administer undiluted or further diluted in NS to a concentration of 20 mg/mL (Bahetwar 2011; Louon 1994; Surendar 2014; Yeaman 2014). Administer half dose in each nostril using a needleless syringe or mucosal atomizer device. <b>Note:</b> Intranasal use for adults for procedural sedation is not recommended since volume limits an adequate dose (Rech 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Mix the appropriate dose (using the injectable solution) in cola or other beverage; administer immediately after preparation (Gutstein 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject deep IM into large muscle mass.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: According to the manufacturer, administer bolus/induction doses over 1 minute or at a rate of 0.5 mg/kg/minute; more rapid administration may result in respiratory depression and enhanced pressor response. Some experts suggest administration over 2 to 3 minutes (Miller 2010). May also be administered as a continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal (using parenteral dosage form): May use the 50 mg/mL solution undiluted or use the 100 mg/mL solution and further dilute prior to administration (Tanaka 2000; Van der Bijl 1991)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185709\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia:</b> Induction and maintenance of general anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726701\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Analgesia (subanesthetic dosing); Complex regional pain syndrome; Depressive episode associated with major depressive disorder and bipolar disorder, treatment Refractory; Procedural sedation/analgesia; Status epilepticus (refractory)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185772\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ketalar may be confused with Kenalog, ketorolac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV, intranasal/inhaled administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185700\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Prolonged emergence from anesthesia (12%; includes confusion, delirium, dreamlike state, excitement, hallucinations, irrational behavior, vivid imagery)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, cardiac arrhythmia, hypotension, increased blood pressure, increased pulse</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drug dependence, hypertonia (tonic-clonic movements sometimes resembling seizures), increased cerebrospinal fluid pressure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (transient), morbilliform rash (transient), rash at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Central diabetes insipidus (Hatab 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, nausea, sialorrhea (Hatab 2014), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary (reactions can be severe in patients with a history of chronic ketamine use/abuse): Bladder dysfunction (reduced capacity), cystitis (including cystitis noninfective, cystitis interstitial, cystitis ulcerative, cystitis erosive, cystitis hemorrhagic), dysuria, hematuria, urinary frequency, urinary incontinence, urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Laryngospasm</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Diplopia, increased intraocular pressure, nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Hydronephrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Airway obstruction, apnea, respiratory depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185713\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ketamine or any component of the formulation; conditions in which an increase in blood pressure would be hazardous</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In the emergency department, the following additional absolute contraindications according to the American College of Emergency Physicians have been asserted (ACEP [Green 2011]): Infants &lt;3 months of age; known or suspected schizophrenia (even if currently stable or controlled with medications)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of cerebrovascular accident; severe cardiac decompensation; surgery of the pharynx, larynx, or bronchial tree unless adequate muscle relaxants are used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185697\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Airway complications: When used for procedural sedation for major procedures involving the posterior pharynx (eg, endoscopy) or when used for patients with an active pulmonary infection or disease (including upper respiratory disease or asthma), the use of ketamine increases the risk of laryngospasm. Patients with a history of airway instability, tracheal surgery, or tracheal stenosis may be at a higher risk of airway complications. The American College of Emergency Physicians considers these situations relative contraindications for the use of ketamine (ACEP [Green 2011]). The manufacturer recommends against the use of ketamine alone in surgery or diagnostic procedures of the pharynx, larynx, or bronchial tree; mechanical stimulation of the pharynx should be avoided, whenever possible, if ketamine is used alone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). When used for outpatient surgery, the patient should be accompanied by a responsible adult. Driving, operating hazardous machinery, or engaging in hazardous activities should not be undertaken for &ge;24 hours after anesthesia, according to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dependence: May cause dependence (withdrawal symptoms on discontinuation) and tolerance with prolonged use. A withdrawal syndrome with psychotic features has been described following discontinuation of long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Emergence reactions: Postanesthetic emergence reactions, which can manifest as vivid dreams, hallucinations, and/or frank delirium, occur; these reactions are less common in patients &lt;16 years of age and &gt;65 years and when given IM (White 1982). Emergence reactions, confusion, or irrational behavior may occur up to 24 hours postoperatively and may be reduced by pretreatment with a benzodiazepine, use of ketamine at the lower end of the dosing range, and minimizing verbal and tactile stimulation of the patient during the recovery period. Avoid use in patients with schizophrenia; may exacerbate psychotic symptoms (Lahti 1995; Malhotra 1997). The American College of Emergency Physicians considers the use of ketamine in patients with known or suspected schizophrenia (even if currently stable or controlled with medications) an absolute contraindication (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Some consider the use of ketamine in patients with CNS masses, CNS abnormalities, or hydrocephalus a relative contraindication due to multiple reports that ketamine may increase intracranial pressure in these patients (ACEP [Green 2011]). However, assuming adequate ventilation, some evidence suggests that ketamine has minimal effects on intracranial pressure and may even improve cerebral perfusion and reduce intracranial pressure (Albanese 1997; Bowles 2012; Zeiler 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased ocular pressure: Use with caution in patients with increased intraocular pressure (IOP). Some recommend avoiding use in patients with an open eye injury or other ophthalmologic disorder where an increase in IOP would prove to be detrimental; however, the effects of ketamine on IOP is mixed with some evidence demonstrating no clinically significant effect on IOP (ACEP [Green 2011]; Cunningham 1986; Drayna 2012; Miller 2010; Nagdeve 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: The American College of Emergency Physicians considers the use of ketamine in patients with porphyria a relative contraindication due to enhanced sympathomimetic effect produced by ketamine (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Rapid IV administration or overdose may cause respiratory depression or apnea. Resuscitative equipment should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: The American College of Emergency Physicians considers the use of ketamine in patients with a thyroid disorder or receiving a thyroid medication a relative contraindication due to enhanced sympathomimetic effect produced by ketamine (ACEP [Green 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, catecholamine depletion, hypertension, and tachycardia. Cardiac function should be continuously monitored in patients with increased blood pressure or cardiac decompensation. Ketamine increases blood pressure, heart rate, and cardiac output thereby increasing myocardial oxygen demand. The mechanism by which ketamine causes a sympathetic surge to stimulate the cardiovascular system has yet to be elucidated. The use of concurrent benzodiazepine, inhaled anesthetics, and propofol or administration of ketamine as a continuous infusion may reduce these cardiovascular effects (Miller 2010). The American College of Emergency Physicians recommends avoidance in patients who are already hypertensive and in older adults with risk factors for coronary artery disease (ACEP [Green 2011]). In a scientific statement from the American Heart Association, ketamine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrospinal fluid (CSF) pressure elevation: Use with caution in patients with CSF pressure elevation; an increase in CSF pressure may be associated with use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Use with caution in the chronic alcoholic or acutely alcohol-intoxicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk versus benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Use requires careful patient monitoring, should only be used by experienced personnel who are not actively engaged in the procedure or surgery. If used in a nonintubated and/or nonmechanically ventilated patient, qualified personnel and appropriate equipment for rapid institution of respiratory and/or cardiovascular support must be immediately available. Use to induce moderate (conscious) sedation in patients warrants monitoring equivalent to that seen with deep anesthesia. Consult local regulations and individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185759\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (major), CYP2C9 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185702\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8588&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inducers (Moderate): May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Ketamine may enhance the adverse/toxic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5994626\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Adverse events have been observed in animal reproduction studies. Ketamine crosses the placenta and can be detected in fetal tissue. Ketamine produces dose dependent increases in uterine contractions; effects may vary by trimester. The plasma clearance of ketamine is reduced during pregnancy. Dose related neonatal depression and decreased APGAR scores have been reported with large doses administered at delivery (Ghoneim 1977; Little 1972; White 1982). Although ketamine has been used during vaginal delivery and cesarean section, use in pregnancy, including obstetrics (either vaginal or abdominal delivery) is not recommended by the manufacturer (Akamatsu 1974; Little 1972; Mercier 1998).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity, may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with ketamine during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570985\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ketamine is present in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185705\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, respiratory rate, transcutaneous O<sub>2</sub> saturation, emergence reactions; cardiac function should be continuously monitored in patients with increased blood pressure or cardiac decompensation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185696\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces a cataleptic-like state in which the patient is dissociated from the surrounding environment by direct action on the cortex and limbic system. Ketamine is a noncompetitive NMDA receptor antagonist that blocks glutamate. Low (subanesthetic) doses produce analgesia, and modulate central sensitization, hyperalgesia and opioid tolerance. Reduces polysynaptic spinal reflexes. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185712\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Anesthetic effect: Within 30 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Anesthetic effect: 3 to 4 minutes; Analgesia: Within 10 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Analgesic effect: Within 10 minutes (Carr 2004); Sedation: Children 2 to 6 years: 5 to 8 minutes (Bahetwar 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Analgesia: Within 30 minutes; Sedation: Children 2 to 8 years (Turhanoglu 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">4 mg/kg/dose: 12.9 &plusmn; 1.9 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">6 mg/kg/dose: 10.4 &plusmn; 2.9 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">8 mg/kg/dose: 9.5 &plusmn; 1.9 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Anesthetic effect: 5 to 10 minutes; Recovery: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Anesthetic effect: 12 to 25 minutes; Analgesia: 15 to 30 minutes; Recovery: 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Analgesic effect: Up to 60 minutes (Carr 2004); Recovery: Children 2 to 6 years: 34 to 46 minutes (Bahetwar 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 2.4 L/kg (Wagner 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 27% (Brunton 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via N-dealkylation (metabolite I [norketamine]), hydroxylation of the cyclohexone ring (metabolites III and IV), conjugation with glucuronic acid and dehydration of the hydroxylated metabolites to form the cyclohexene derivative (metabolite II); metabolite I (norketamine) is 33% as potent as parent compound. When administered orally, norketamine concentrations are higher compared to other routes of administration due to extensive first-pass metabolism in the liver (Blonk 2010; Soto 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 93%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 20% to 30% (Miller 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Children, Adolescents, and Adults: Mean range: 35% to 50% (Malinovsky 1996; Miller 2010; Nielsen 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: Children 2 to 9 years: 25% (Malinovsky 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Alpha: 10 to 15 minutes; Beta: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 5 to 30 minutes (Clements 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: 10 to 14 minutes (Huge 2010); Children 2 to 9 years: ~20 minutes (Malinovsky 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: ~30 minutes (Soto 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: Children 2 to 9 years: ~45 minutes (Malinovsky 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (91%); feces (3%) (Ghoneim 1977)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422244\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ketalar Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $21.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (10 mL): $6.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $11.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ketamine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $20.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (10 mL): $4.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $9.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Ketamine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $6.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/2 mL (2 mL): $6.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Ketamine HCl-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20MG/2ML 0.9% (2 mL): $5.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/5ML 0.9% (5 mL): $5.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MG/10ML 0.9% (10 mL): $8.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185716\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aneket (ET, LK);</li>\n      <li>Anesject (ID);</li>\n      <li>Brevinaze (ZA);</li>\n      <li>Calypsol (AE, BB, BG, BH, BM, BS, BZ, CY, CZ, EG, GY, HN, HU, IQ, IR, JM, JO, KW, LB, LY, OM, PK, PL, PR, QA, RO, RU, SA, SR, SY, TT, VN, YE);</li>\n      <li>Cost (AR, BR);</li>\n      <li>Etamine (PH);</li>\n      <li>Ivanes (ID);</li>\n      <li>Kain (BD);</li>\n      <li>Kanox (MY);</li>\n      <li>Katalar (QA);</li>\n      <li>Keiran (VE);</li>\n      <li>Ketalar (AE, AU, BB, BD, BE, BH, BM, BS, BZ, CH, CY, DK, EE, EG, FI, FR, GB, GR, GY, HK, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KW, LB, LU, LY, MT, MY, NO, NZ, OM, PE, PT, QA, SA, SE, SK, SR, SY, TR, TT, TW, UY, YE);</li>\n      <li>Ketalin (MX);</li>\n      <li>Ketam (BD, ET);</li>\n      <li>Ketamax (PH);</li>\n      <li>Ketamin-S (+) (PY);</li>\n      <li>Ketamina (CU);</li>\n      <li>Ketanest (AT, HR, NL, PL);</li>\n      <li>Ketanir (LK);</li>\n      <li>Ketaride (BD);</li>\n      <li>Ketashort (CO);</li>\n      <li>Ketava (MY);</li>\n      <li>Ketavit (LK);</li>\n      <li>Ketmin (IN);</li>\n      <li>Ketolar (ES);</li>\n      <li>Ketomin (KR);</li>\n      <li>Narkamon (DE, PL);</li>\n      <li>Tekam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Velonarcon (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19897179\"></a>aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. <i>Biol Psychiatry</i>. 2010;67(2):139-145. doi: 10.1016/j.biopsych.2009.08.038.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19897179/pubmed\" target=\"_blank\" id=\"19897179\">19897179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2011;117(2 Pt 1):420-421. doi: 10.1097/AOG.0b013e31820eede9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21252774/pubmed\" target=\"_blank\" id=\"21252774\">21252774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adam F, Chauvin M, Du Manoir B, et al, &quot;Small-Dose Ketamine Infusion Improves Postoperative Analgesia and Rehabilitation After Total Knee Arthroplasty,&quot; <i>Anesth Analg</i>, 2005, 100(2):475-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15673878/pubmed\" target=\"_blank\" id=\"15673878\">15673878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. <i>Neurology</i>. 2013;80(7):642-647.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23365053/pubmed\" target=\"_blank\" id=\"23365053\">23365053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akamatsu TJ, Bonica JJ, Rehmet R, Eng M, Ueland K. Experiences with the use of ketamine for parturition. I. Primary anesthetic for vaginal delivery. <i>Anesth Analg</i>. 1974;53(2):284-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/4856139/pubmed\" target=\"_blank\" id=\"4856139\">4856139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9416717\"></a>Alban&egrave;se J, Arnaud S, Rey M, Thomachot L, Alliez B, Martin C. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. <i>Anesthesiology</i>. 1997;87(6):1328-1334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9416717/pubmed\" target=\"_blank\" id=\"9416717\">9416717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23222112\"></a>Alletag MJ, Auerbach MA, Baum CR. Ketamine, propofol, and ketofol use forpediatric sedation. <i>Pediatr Emerg Care</i>. 2012;28(12):1391-1395; quiz 1396-8. doi:10.1097/PEC.0b013e318276fde2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23222112/pubmed\" target=\"_blank\" id=\"23222112\">23222112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andolfatto G, Willman E, Joo D, et al. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. <i>Acad Emerg Med</i>. 2013;20(10):1050-1054.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24127709/pubmed\" target=\"_blank\" id=\"24127709\">24127709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22401952\"></a>Andolfatto G, Abu-Laban RB, Zed PJ, et al. Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial.<i> Ann Emerg Med</i>. 2012;59(6):504-512.e1-e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22401952/pubmed\" target=\"_blank\" id=\"22401952\">22401952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23364373\"></a>Asadi P, Ghafouri HB, Yasinzadeh M, Kasnavieh SM, Modirian E. Ketamine and atropine for pediatric sedation: a prospective double-blind randomized controlled trial. <i>Pediatr Emerg Care</i>. 2013;29(2):136-139. doi: 10.1097/PEC.0b013e31828058b2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23364373/pubmed\" target=\"_blank\" id=\"23364373\">23364373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahetwar SK, Pandey RK, Saksena AK, etal. A comparative evaluation of intranasal midazolam, ketamine and their combination for sedation of young uncooperative pediatric dental patients: a triple blind randomized crossover trial. <i>J Clin Pediatr Dent</i>. 2011;35(4):415-420.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22046702/pubmed\" target=\"_blank\" id=\"22046702\">22046702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23188232\"></a>Ballow SL, Kaups KL, Anderson S, Chang M. A standardized rapid sequence intubation protocol facilitates airway management in critically injured patients. <i>J Trauma Acute Care Surg</i>. 2012;73(6):1401-1405. doi:10.1097/TA.0b013e318270dcf5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23188232/pubmed\" target=\"_blank\" id=\"23188232\">23188232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barash PG, Cullen BF, Stoelting RK, et al, eds, <i>Clinical Anesthesia</i>, 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23686730\"></a>Barkan S, Breitbart R, Brenner-Zada G, et al. A double-blind, randomised, placebo-controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair. <i>Emerg Med J</i>. 2014;31(8):649-653. doi:10.1136/emermed-2012-202189.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23686730/pubmed\" target=\"_blank\" id=\"23686730\">23686730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit. <i>Crit Care Med.</i> 2013;41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1443705\"></a>Beebe DS, Belani KG, Chang PN, et al. Effectiveness of preoperative sedation with rectal midazolam, ketamine, or their combination in young children. <i>Anesth Analg</i>. 1992;75(6):880-884.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1443705/pubmed\" target=\"_blank\" id=\"1443705\">1443705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15006978\"></a>Berkenbosch JW, Graff GR, Stark JM. Safety and efficacy of ketamine sedation for infant flexible fiberoptic bronchoscopy. <i>Chest</i>. 2004;125(3):1132-1137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15006978/pubmed\" target=\"_blank\" id=\"15006978\">15006978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19879174\"></a>Blonk MI, Koder BG, van den Bemt PM, Huygen FJ. Use of oral ketamine in chronic pain management: a review. <i>Eur J Pain</i>. 2010;14(5):466-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19879174/pubmed\" target=\"_blank\" id=\"19879174\">19879174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowles ED, Gold ME. Rethinking the paradigm: evaluation of ketamine as a neurosurgical anesthetic [published correction appears in <i>AANA J</i>. 2013 ;81(1):18.]. <i>AANA J</i>. 2012;80(6):445-452.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23409639/pubmed\" target=\"_blank\" id=\"23409639\">23409639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunton LL, Lazo JS, Park KL, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 11th ed. New York, NY: McGraw-Hill Medical; 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15109503\"></a>Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. <i>Pain</i>. 2004;108(1-2):17-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15109503/pubmed\" target=\"_blank\" id=\"15109503\">15109503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Christie JM, Jones CW, Markowsky SJ. Chemical compatibility of regional anesthetic drug combinations. <i>Ann Pharmacother</i>. 1992;26(9):1078-1080.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1421668/pubmed\" target=\"_blank\" id=\"1421668\">1421668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. <i>J Pharm Sci</i>. 1982;71(5):539-542.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7097501/pubmed\" target=\"_blank\" id=\"7097501\">7097501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corrigan M, Wilson SS, Hampton J. Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. <i>Am J Health Syst Pharm</i>. 2015;72(18):1544-1554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26346210/pubmed\" target=\"_blank\" id=\"26346210\">26346210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cote CJ, &quot;Sedation for the Pediatric Patient: A Review,&quot; <i>Pediatr Clin North Am</i>, 1994, 41(1):31-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8295806/pubmed\" target=\"_blank\" id=\"8295806\">8295806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cot&eacute; CJ, Lerman J, Anderson BJ, eds. <i>A Practice of Anesthesia for Infants and Children.</i> 5th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham AJ, Barry P. Intraocular pressure--physiology and implications for anaesthetic management. <i>Can Anaesth Soc J</i>. 1986 Mar;33(2):195-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/3516335/pubmed\" target=\"_blank\" id=\"3516335\">3516335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21256626\"></a>David H, Shipp J. A randomized controlled trial of ketamine/propofol versus propofol alone for emergency department procedural sedation. <i>Ann Emerg Med</i>. 2011;57(5):435-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21256626/pubmed\" target=\"_blank\" id=\"21256626\">21256626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16567251\"></a>Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation insevere pediatric asthma. <i>J Emerg Med</i>. 2006;30(2):163-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/16567251/pubmed\" target=\"_blank\" id=\"16567251\">16567251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9243683\"></a>Diaz JH. Intranasal ketamine preinduction of paediatric outpatients. <i>Paediatr Anaesth</i>. 1997;7(4):273-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9243683/pubmed\" target=\"_blank\" id=\"9243683\">9243683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22169582\"></a>Drayna PC, Estrada C, Wang W, Saville BR, Arnold DH. Ketamine sedation is not associated with clinically meaningful elevation of intraocular pressure. <i>Am J Emerg Med</i>. 2012;30(7):1215-1218. doi: 10.1016/j.ajem.2011.06.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22169582/pubmed\" target=\"_blank\" id=\"22169582\">22169582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Drug Safety Communication. FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. Food and Drug Administration website. <a href=\"https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Accessed May 26, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Felser JM and Orban DJ, &quot;Dystonic Reaction After Ketamine Abuse,&quot; <i>Ann Emerg Med</i>, 1982, 11(12):673-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7149360/pubmed\" target=\"_blank\" id=\"7149360\">7149360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25038867\"></a>Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. <i>Psychopharmacology (Berl)</i>. 2014;231(18):3663-3676. doi:10.1007/s00213-014-3664-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25038867/pubmed\" target=\"_blank\" id=\"25038867\">25038867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Philadelphia, PA: Elsevier Health; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funk W, Jakob W, Riedl T, Taeger K. Oral preanaesthetic medication for children: double-blind randomized study of a combination of midazolam and ketamine vs midazolam or ketamine alone. <i>Br J Anaesth</i>. 2000;84(3):335-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10793592/pubmed\" target=\"_blank\" id=\"10793592\">10793592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23758557\"></a>Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. <i>Epilepsia</i>. 2013;54(8):1498-1503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23758557/pubmed\" target=\"_blank\" id=\"23758557\">23758557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18092436\"></a>Gautam SN, Bhatta S, Sangraula D, Shrestha BC, Rawal SB. Intranasal midazolam Vs ketamine as premedication in paediatric surgical procedure for childseparation and induction. <i>Nepal Med Coll J</i>. 2007;9(3):179-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/18092436/pubmed\" target=\"_blank\" id=\"18092436\">18092436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghoneim MM and Korttila K, &quot;Pharmacokinetics of Intravenous Anaesthetics: Implications for Clinical Use,&quot; <i>Clin Pharmacokinet</i>, 1977, 2(5):344-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21053/pubmed\" target=\"_blank\" id=\"21053\">21053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glickman A, &quot;Ketamine: The Dissociative Anesthetic and the Development of a Policy for Its Safe Administration in the Pediatric Emergency Department,&quot; <i>J Emerg Nurs</i>, 1995, 21(2):116-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7776601/pubmed\" target=\"_blank\" id=\"7776601\">7776601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godwin SA, Burton JH, Gerardo CJ, et al; American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2014;63(2):247-258.e18. doi: 10.1016/j.annemergmed.2013.10.015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24438649/pubmed\" target=\"_blank\" id=\"24438649\">24438649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. <i>Acad Emerg Med</i>. 2000;7(3):278-281.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10730837/pubmed\" target=\"_blank\" id=\"10730837\">10730837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green SM and Johnson NE, &quot;Ketamine Sedation for Pediatric Procedures: Part 2, Review and Implications,&quot; <i>Ann Emerg Med</i>, 1990, 19(9):1033-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/2203290/pubmed\" target=\"_blank\" id=\"2203290\">2203290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21256625\"></a>Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline foremergency department ketamine dissociative sedation: 2011 update. <i>Ann Emerg Med.</i> 2011;57(5):449-461. doi: 10.1016/j.annemergmed.2010.11.030.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21256625/pubmed\" target=\"_blank\" id=\"21256625\">21256625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guillou N, Tanguy M, Sequin P, et al, &ldquo;The Effects of Small-Dose Ketamine on Morphine Consumption in Surgical Intensive Care Unit Patients After Major Abdominal Surgery,&rdquo; <i>Anesth Analg</i>, 2003, 97(3):384-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/12933413/pubmed\" target=\"_blank\" id=\"12933413\">12933413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1729932\"></a>Gutstein HB, Johnson KL, Heard MB, Gregory GA. Oral ketamine preanesthetic medication in children. <i>Anesthesiology</i>. 1992;76(1):28-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1729932/pubmed\" target=\"_blank\" id=\"1729932\">1729932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23800984\"></a>Gyanesh P, Haldar R, Srivastava D, Agrawal PM, Tiwari AK, Singh PK. Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication forprocedural sedation in children undergoing MRI: a double-blind, randomized,placebo-controlled trial. <i>J Anesth</i>. 2014;28(1):12-18. doi:10.1007/s00540-013-1657-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23800984/pubmed\" target=\"_blank\" id=\"23800984\">23800984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartvig P, Larsson E, Joachimsson PO. Postoperative Analgesia and Sedation Following Pediatric Cardiac Surgery Using a Constant Infusion of Ketamine. <i>J Cardiothorac Vasc Anesth. </i>1993;7(2):148-153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8477017/pubmed\" target=\"_blank\" id=\"8477017\">8477017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartvig P, Valtysson J, Lindner KJ, et al. Central Nervous System Effects of Subdissociative Doses of (<i>S</i>)-Ketamine Are Related to Plasma and Brain Concentrations Measured With Positron Emission Tomography in Healthy Volunteers. <i>Clin Pharmacol Ther.</i> 1995;58(2):165-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7648766/pubmed\" target=\"_blank\" id=\"7648766\">7648766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hatab SZ, Singh A, Felner EI, Kamat P. Transient central diabetes insipidus induced by ketamine infusion.<i> Ann Pharmacother</i>. 2014;48(12):1642-1645.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25225198 /pubmed\" target=\"_blank\" id=\"25225198 \">25225198 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18245435\"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.doi: 10.1542/peds.2007-3284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15343462\"></a>Heinrich M, Wetzstein V, Muensterer OJ, Till H. Conscious sedation: Off-label use of rectal S(+)-ketamine and midazolam for wound dressing changes inpaediatric heat injuries. <i>Eur J Pediatr Surg</i>. 2004;14(4):235-239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15343462/pubmed\" target=\"_blank\" id=\"15343462\">15343462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hocking G and Cousins MJ, &quot;Ketamine in Chronic Pain Management: An Evidence-Based Review,&quot; <i>Anesth Analg</i>, 2003, 97(6):1730-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/14633551/pubmed\" target=\"_blank\" id=\"14633551\">14633551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huge V, Lauchart M, Magerl W, et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. <i>Eur J Pain</i>. 2010;14(4):387-394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19733106/pubmed\" target=\"_blank\" id=\"19733106\">19733106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ketalar (ketamine hydrochloride) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ketalar (ketamine hydrochloride) [product monograph]. Montreal, Quebec, Canada: ERFA Canada; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ketamine hydrochloride injection [prescribing information]. Lake Forest, IL: Hospira Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kohrs R and Durieux ME, &quot;Ketamine: Teaching an Old Drug New Tricks,&quot; <i>Anesth Analg</i>, 1998, 87(5):1186-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9806706/pubmed\" target=\"_blank\" id=\"9806706\">9806706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20924617\"></a>Koruk S, Mizrak A, Gul R, Kilic E, Yendi F, Oner U. Dexmedetomidine-ketamineand midazolam-ketamine combinations for sedation in pediatric patients undergoingextracorporeal shock wave lithotripsy: a randomized prospective study. <i>J Anesth</i>. 2010;24(6):858-863. doi: 10.1007/s00540-010-1023-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20924617/pubmed\" target=\"_blank\" id=\"20924617\">20924617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23703410\"></a>Kosharskyy B, Almonte W, Shaparin N, Pappagallo M, Smith H. Intravenous infusions in chronic pain management. <i>Pain Physician</i>. 2013;16(3):231-249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23703410/pubmed\" target=\"_blank\" id=\"23703410\">23703410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22237581\"></a>Kramer AH. Early ketamine to treat refractory status epilepticus. <i>Neurocrit Care</i>. 2012;16(2):299-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22237581/pubmed\" target=\"_blank\" id=\"22237581\">22237581</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10738053\"></a>Krauss B and Green SM, Sedation and analgesia for procedures in children. <i>N Engl J Med</i>. 2000;342(13):938-945.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10738053/pubmed\" target=\"_blank\" id=\"10738053\">10738053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lahti AC, Koffel B, LaPorte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. <i>Neuropsychopharmacology</i>. 1995 Aug;13(1):9-19<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8526975/pubmed\" target=\"_blank\" id=\"8526975\">8526975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2215104\"></a>Lin SM, Liu K, Tsai SK, Lee TY. Rectal ketamine versus intranasal ketamine as premedicant in children. <i>Ma Zui Xue Za Zhi</i>. 1990;28(2):177-183.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/2215104/pubmed\" target=\"_blank\" id=\"2215104\">2215104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15675923\"></a>Lin C, Durieux ME. Ketamine and kids: an update. <i>Paediatr Anaesth</i>. 2005;15(2):91-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15675923/pubmed\" target=\"_blank\" id=\"15675923\">15675923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Little B, Chang T, Chucot L, et al, &quot;Study of Ketamine as an Obstetric Anesthetic Agent,&quot; <i>Am J Obstet Gynecol </i>, 1972, 15:113(2):247-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/4554554/pubmed\" target=\"_blank\" id=\"4554554\">4554554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loftus RW, Yeager MP, Clark JA, et al, &quot;Intraoperative Ketamine Reduces Perioperative Opiate Consumption in Opiate-Dependent Patients With Chronic Back Pain Undergoing Back Surgery,&quot; <i>Anesthesiology</i>, 2010, 113(3):639-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20693876/pubmed\" target=\"_blank\" id=\"20693876\">20693876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8023666\"></a>Louon A, Reddy VG. Nasal midazolam and ketamine for paediatric sedation during computerised tomography. <i>Acta Anaesthesiol Scand</i>. 1994;38(3):259-261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8023666/pubmed\" target=\"_blank\" id=\"8023666\">8023666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. <i>Neuropsychopharmacology</i>. 1997 Sep;17(3):141-150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9272481/pubmed\" target=\"_blank\" id=\"9272481\">9272481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. <i>Br J Anaesth</i>. 1996;77(2):203-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8881626/pubmed\" target=\"_blank\" id=\"8881626\">8881626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx GF, Hwang HS, and Chandra P, &quot;Postpartum Uterine Pressures With Different Doses of Ketamine,&quot; <i>Anesthesiology</i>, 1979, 50(2):163-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/571254/pubmed\" target=\"_blank\" id=\"571254\">571254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25010396\"></a>McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. <i>Psychol Med</i>. 2015;45(4):693-704. doi: 10.1017/S0033291714001603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25010396/pubmed\" target=\"_blank\" id=\"25010396\">25010396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGlone RG, Howes MC, and Joshi M, &quot;The Lancaster Experience of 2.0 to 2.5 mg/kg Intramuscular Ketamine for Paediatric Sedation: 501 Cases and Analysis,&quot; <i>Emerg Med J</i>, 2004, 21(3):290-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15107365/pubmed\" target=\"_blank\" id=\"15107365\">15107365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mellon RD, Simone AF, and Rappaport BA, &quot;Use of Anesthetic Agents in Neonates and Young Children,&quot; <i>Anesth Analg</i>, 2007, 104(3):509-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17312200/pubmed\" target=\"_blank\" id=\"17312200\">17312200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menigaux C, Fletcher D, Dupont X, et al, &quot;The Benefits of Intraoperative Small-Dose Ketamine on Postoperative Pain After Anterior Cruciate Ligament Repair,&quot; <i>Anesth Analg</i>, 2000, 90(1):129-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10624993/pubmed\" target=\"_blank\" id=\"10624993\">10624993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mercadante S, &quot;Ketamine in Cancer Pain: An Update,&quot; <i>Palliat Med</i>, 1996, 10(3):225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8817593/pubmed\" target=\"_blank\" id=\"8817593\">8817593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mercier FJ, Benhamou D. Promising non-narcotic analgesic techniques for labour. <i>Baillieres Clin Obstet Gynaecol</i>. 1998;12(3):397-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10023428/pubmed\" target=\"_blank\" id=\"10023428\">10023428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moro-Sutherland DM and Shook JE, &quot;Ketamine Use in a Pediatric Emergency Room,&quot; <i>Acad Emerg Med</i>, 1995, 2:428-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mortero RF, Clark LD, Tolan MM, et al, &quot;The Effects of Small-Dose Ketamine on Propofol Sedation: Respiration, Postoperative Mood, Perception, Cognition, and Pain,&quot; <i>Anesth Analg</i>, 2001, 92(6):1465-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/11375826/pubmed\" target=\"_blank\" id=\"11375826\">11375826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22840761\"></a>Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. <i>Biol Psychiatry</i>. 2013;74(4):250-256. doi: 10.1016/j.biopsych.2012.06.022.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/22840761/pubmed\" target=\"_blank\" id=\"22840761\">22840761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagdeve NG, Yaddanapudi S, Pandav SS. The effect of different doses of ketamine on intraocular pressure in anesthetized children. <i>J Pediatr Ophthalmol Strabismus</i>. 2006 Jul-Aug;43(4):219-223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/16915900/pubmed\" target=\"_blank\" id=\"16915900\">16915900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26423481\"></a>Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. <i>Am J Psychiatry</i>. 2015;172(10):950-966. doi: 10.1176/appi.ajp.2015.15040465.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/26423481/pubmed\" target=\"_blank\" id=\"26423481\">26423481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nielsen BN, Friis SM, R&oslash;msing J, et al. Intranasal sufentanil/ketamine analgesia in children. <i>Paediatr Anaesth</i>. 2014;24(2):170-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24118506/pubmed\" target=\"_blank\" id=\"24118506\">24118506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23480923\"></a>Norambuena C, Ya&ntilde;ez J, Flores V, Puentes P, Carrasco P, Villena R. Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized,double-blind study. <i>J Pediatr Surg</i>. 2013;48(3):629-634. doi:10.1016/j.jpedsurg.2012.08.018.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23480923/pubmed\" target=\"_blank\" id=\"23480923\">23480923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okon T. Ketamine: an introduction for the pain and palliative medicine physician. <i>Pain Physician</i>. 2007;10(3):493-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17525784/pubmed\" target=\"_blank\" id=\"17525784\">17525784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15357562\"></a>Ozdemir D, Kayserili E, Arslanoglu S, Gulez P, Vergin C. Ketamine and midazolam for invasive procedures in children with malignancy: a comparison ofroutes of intravenous, oral, and rectal administration. <i>J Trop Pediatr</i>. 2004;50(4):224-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15357562/pubmed\" target=\"_blank\" id=\"15357562\">15357562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23428794\"></a>Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. <i>J Psychopharmacol</i>. 2013;27(5):444-450. doi: 10.1177/0269881113478283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/23428794/pubmed\" target=\"_blank\" id=\"23428794\">23428794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rech MA, Barbas B, Chaney W, et al. When to Pick the Nose: Out-of-Hospital and Emergency Department Intranasal Administration of Medications [published ahead of print March 25, 2017]. <i>Ann Emerg Med.</i> 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10875722/pubmed\" target=\"_blank\" id=\"10875722\">10875722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reeker W, Werner C, Mollenberg O, et al, &quot;High-Dose S(+)-ketamine Improves Neurological Outcome Following Incomplete Cerebral Ischemia in Rats,&quot; <i>Can J Anesth</i>, 2000, 47(6):572-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/10875722/pubmed\" target=\"_blank\" id=\"10875722\">10875722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rem&eacute;rand F, Le Tendre C, Baud A, et al, &quot;The Early and Delayed Analgesic Effects of Ketamine After Total Hip Arthroplasty: A Prospective, Randomized, Controlled, Double-Blind Study,&quot; <i>Anesth Analg</i>, 2009, 109(6):1963-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/19923527/pubmed\" target=\"_blank\" id=\"19923527\">19923527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3698618\"></a>Rock MJ, Reyes de la Rocha S, L'Hommedieu CS, Truemper E. Use of ketamine inasthmatic children to treat respiratory failure refractory to conventionaltherapy. <i>Crit Care Med</i>. 1986;14(5):514-516.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/3698618/pubmed\" target=\"_blank\" id=\"3698618\">3698618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15675259\"></a>Roelofse JA, Shipton EA, de la Harpe CJ, Blignaut RJ. Intranasalsufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in thepediatric population prior to undergoing multiple dental extractions undergeneral anesthesia: a prospective, double-blind, randomized comparison. <i>AnesthProg</i>. 2004;51(4):114-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/15675259/pubmed\" target=\"_blank\" id=\"15675259\">15675259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenberg M, &quot;Oral Ketamine for Deep Sedation of Difficult-to-Manage Children Who are Mentally Handicapped: Case Report,&quot; <i>Pediatr Dent</i>, 1991, 13(4):221-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1832219/pubmed\" target=\"_blank\" id=\"1832219\">1832219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8304605\"></a>Sacchetti A, Schafermeyer R, Gerardi M, et al, &quot;Pediatric Analgesia and Sedation,&quot; <i>Ann Emerg Med</i>, 1994, 23(2):237-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8304605/pubmed\" target=\"_blank\" id=\"8304605\">8304605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20947210\"></a>Shah A, Mosdossy G, McLeod S, Lehnhardt K, Peddle M, Rieder M. A blinded,randomized controlled trial to evaluate ketamine/propofol versus ketamine alonefor procedural sedation in children.<i> Ann Emerg Med</i>. 2011;57(5):425-433.e2.doi: 10.1016/j.annemergmed.2010.08.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20947210/pubmed\" target=\"_blank\" id=\"20947210\">20947210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shannon M, &quot;Recent Ketamine Administration Can Produce a Urine Toxic Screen Which Is Falsely Positive for Phencyclidine,&quot; <i>Pediatr Emerg Care</i>, 1998, 14(2):180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9583407/pubmed\" target=\"_blank\" id=\"9583407\">9583407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24268616\"></a>Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. <i>J Affect Disord</i>. 2014;155:123-129. doi: 10.1016/j.jad.2013.10.036.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24268616/pubmed\" target=\"_blank\" id=\"24268616\">24268616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soto E, Stewart DR, Mannes AJ, et al. Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndrome. <i>Am J Hosp Palliat Care</i>. 2012; 29(4): 308&ndash;317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/21803784/pubmed\" target=\"_blank\" id=\"21803784\">21803784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart KG, Rowbottom SJ, Aitken AW, Rajendram S, Sudhaman DA. Oral ketamine premedication for paediatric cardiac surgery--a comparison with intramuscular morphine (both after oral trimeprazine). <i>Anaesth Intensive Care</i>. 1990;18(1):11-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/2186655/pubmed\" target=\"_blank\" id=\"2186655\">2186655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18544145\"></a>Sungur Ulke Z, Kartal U, Orhan Sungur M, Camci E, Tugrul M. Comparison of sevoflurane and ketamine for anesthetic induction in children with congenital heart disease. <i>Paediatr Anaesth</i>. 2008;18(8):715-21. doi:10.1111/j.1460-9592.2008.02637.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/18544145/pubmed\" target=\"_blank\" id=\"18544145\">18544145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25095322\"></a>Surendar MN, Pandey RK, Saksena AK, Kumar R, Chandra G. A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. <i>J Clin Pediatr Dent</i>. 2014;38(3):255-261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/25095322/pubmed\" target=\"_blank\" id=\"25095322\">25095322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11046209\"></a>Tanaka M, Sato M, Saito A, Nishikawa T. Reevaluation of rectal ketamine premedication in children: comparison with rectal midazolam. <i>Anesthesiology</i>. 2000;93(5):1217-1224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/11046209/pubmed\" target=\"_blank\" id=\"11046209\">11046209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2379394\"></a>Tobias JD, Martin LD, Wetzel RC. Ketamine by continuous infusion for sedation in the pediatric intensive care unit. <i>Crit Care Med</i>. 1990;18(8):819-821.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/2379394/pubmed\" target=\"_blank\" id=\"2379394\">2379394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1408506\"></a>Tobias JD, Phipps S, Smith B, Mulhern RK. Oral ketamine premedication to alleviate the distress of invasive procedures in pediatric oncology patients. <i>Pediatrics</i>. 1992;90(4):537-541.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1408506/pubmed\" target=\"_blank\" id=\"1408506\">1408506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD and Rasmussen GE, &quot;Pain Management and Sedation in the Pediatric Intensive Care Unit,&quot; <i>Pediatr Clin North Am</i>, 1994, 41(6):1269-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/7984386/pubmed\" target=\"_blank\" id=\"7984386\">7984386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turhano&#287;lu S, Kararmaz A, Ozyilmaz MA, Kaya S, Tok D. Effects of different doses of oral ketamine for premedication of children. <i>Eur J Anaesthesiol</i>. 2003;20(1):56-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/12553389/pubmed\" target=\"_blank\" id=\"12553389\">12553389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1890517\"></a>van der Bijl P, Roelofse JA, Stander IA. Rectal ketamine and midazolam for premedication in pediatric dentistry.<i> J Oral Maxillofac Surg</i>. 1991;49(10):1050-1054.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/1890517/pubmed\" target=\"_blank\" id=\"1890517\">1890517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner BK, O'Hara DA. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. <i>Clin Pharmacokinet</i>. 1997;33(6):426-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/9435992/pubmed\" target=\"_blank\" id=\"9435992\">9435992</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20865876\"></a>Wang X, Zhou ZJ, Zhang XF, Zheng S. A comparison of two different doses of rectal ketamine added to 0.5 mg x kg(-1) midazolam and 0.02 mg x kg(-1) atropine in infants and young children. <i>Anaesth Intensive Care</i>. 2010;38(5):900-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20865876/pubmed\" target=\"_blank\" id=\"20865876\">20865876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8443849\"></a>Weksler N, Ovadia L, Muati G, Stav A. Nasal ketamine for paediatric premedication. <i>Can J Anaesth</i>. 1993;40(2):119-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8443849/pubmed\" target=\"_blank\" id=\"8443849\">8443849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White PF, Way WL, Trevor AJ. Ketamine &minus; its pharmacology and therapeutic uses. <i>Anesthesiology.</i> 1982;56(2):119-136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/6892475/pubmed\" target=\"_blank\" id=\"6892475\">6892475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17059854\"></a>Willman EV, Andolfatto G. A prospective evaluation of &quot;ketofol&quot;(ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2007;49(1):23-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/17059854/pubmed\" target=\"_blank\" id=\"17059854\">17059854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winters WD. Epilepsy or anesthesia with ketamine. <i>Anesthesiology. </i>1972;36(4):309-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/5020639/pubmed\" target=\"_blank\" id=\"5020639\">5020639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. <i>Biopharm Drug Dispos</i>. 2003;24(1):37-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/12516077/pubmed\" target=\"_blank\" id=\"12516077\">12516077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24712757\"></a>Yeaman F, Meek R, Egerton-Warburton D, Rosengarten P, Graudins A. Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. <i>Emerg Med Australas</i>. 2014;26(3):237-242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24712757/pubmed\" target=\"_blank\" id=\"24712757\">24712757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8905436\"></a>Youssef-Ahmed MZ, Silver P, Nimkoff L, Sagy M. Continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm. <i>Intensive Care Med</i>. 1996;22(9):972-976.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/8905436/pubmed\" target=\"_blank\" id=\"8905436\">8905436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zakine J, Samarcq D, Lorne E, et al, &quot;Postoperative Ketamine Administration Decreases Morphine Consumption in Major Abdominal Surgery: A Prospective, Randomized, Double-Blind, Controlled Study,&quot; <i>Anesth Analg</i>, 2008, 106(6):1856-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/18499623/pubmed\" target=\"_blank\" id=\"18499623\">18499623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20157833\"></a>Zanette G, Micaglio M, Zanette L, Manani G, Facco E. Comparison between ketamine and fentanyl-droperidol for rectal premedication in children: a randomized placebo controlled trial. <i>J Anesth</i>. 2010;24(2):197-203. doi:10.1007/s00540-010-0884-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/20157833/pubmed\" target=\"_blank\" id=\"20157833\">20157833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on ICP in traumatic brain injury. <i>Neurocrit Care</i>. 2014;21(1):163-173. doi: 10.1007/s12028-013-9950-y.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketamine-drug-information/abstract-text/24515638/pubmed\" target=\"_blank\" id=\"24515638\">24515638</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8588 Version 188.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45497290\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F185726\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F185763\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F185729\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F185746\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F185730\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160060\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160061\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F185708\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F185693\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F185765\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F185710\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F185709\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726701\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F185772\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F185700\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F185713\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F185697\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F185759\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F185702\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5994626\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16570985\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F185705\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F185696\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F185712\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422244\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F185716\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8588|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ketamine-patient-drug-information\" class=\"drug drug_patient\">Ketamine: Patient drug information</a></li><li><a href=\"topic.htm?path=ketamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Ketamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}